Back to search results

LaSAR BeaM Study for Recurrent Brain Metastases

This study, called LaSAR BeaM, is for people with brain metastases (cancers that have spread to the brain) that have come back after previous radiation treatment. It's looking at whether adding more radiation (called SRS2) after surgery or LITT (Laser Interstitial Thermal Therapy, a procedure using heat to destroy tumors) helps prevent the cancer from returning locally. Participants will either have surgery or LITT, followed by SRS2 or close monitoring. The main goal is to see how safe these treatments are and if SRS2 improves the time until the cancer comes back. You may be able to join if you are 18 or older and meet certain health criteria. The study plans to enroll 155 people, but its current status is unclear.

Study design
This is an interventional study planning to enroll 155 participants. It compares SRS2 following surgery/LITT to close surveillance following surgery/LITT.
What's involved
Participants will undergo either craniotomy and surgical resection or LITT. Safety and side effects will be measured throughout the study, averaging one year.
Compensation
Not stated in the trial record.
Follow-up
Safety and adverse events will be measured through study completion, which is an average of one year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07053033

Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR BeaM)

Recruiting
PHASE2Ages 18+InterventionalTreatment
M.D. Anderson Cancer Center
~155 participants
Updated 2026-03-09 on ClinicalTrials.gov
What's tested:SurgeryLITT

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and Adverse Events (AEs)
Measured over Through study completion; an average of 1 year

Conditions

Brain Metastases

Explore related trials

Metastatic Malignant Neoplasm in the Brain

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Subha Perni, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Subha Perni, MD
[email protected]
713-563-2543
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Ability to understand and the willingness to sign a written informed consent document.
Willingness to comply with all study procedures and availability for the duration of the study.
Age ≥18 years. Because no dosing or adverse event data are currently available on the use of SRS2, children are excluded from this study.
Karnofsky performance status ≥ 60.
Radiographic concern for progression of a solid tumor brain metastasis that has received prior stereotactic radiosurgery ≥ 3 months prior to study enrollment.
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as ≥5 mm with MRI scan.
Have active tumor on pathology from surgery/LITT for this lesion.
Able to safely undergo MRI imaging.
Acceptable candidate for SRS2 per treating physician and multidisciplinary conference consensus.
Have no radiographic evidence of leptomeningeal disease on radiology report or neuro-radiologist review.
Patients with a prior or concurrent malignancy whose natural history or treatment does not interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.

Exclusion

Patients with brain metastases from hematologic malignancies due to significant differences in radiosensitivity and treatment paradigms.
Patients with psychiatric illness/social situations that would limit compliance with study requirements.
Pregnant women are excluded from this study because radiation has the potential for teratogenic or abortifacient effects. All female patients between the onset of menses and 55 years will receive a pregnancy test prior to SRS2 unless the patient presents with an applicable exclusionary factor which may be one of the following:
Postmenopausal (no menses in greater than or equal to 12 consecutive months).
History of hysterectomy or bilateral salpingo-oophorectomy.
Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).
History of bilateral tubal ligation or another surgical sterilization procedure.

What this trial measures

  • Safety and Adverse Events (AEs)Through study completion; an average of 1 year

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0